Current research projects –
Information for experts
Gutblick Research conducts clinical research projects in various areas of ophthalmology. The focus is on practical issues and high methodological quality. The research projects are carried out in cooperation with clinics, research institutions, and industry partners. Here you will find an overview of current studies, sorted by field of expertise.
Specialists who are interested in collaborating or including their patients in a study can find further information and contact details here.
The quality of Gutblick Research has been verified by external bodies. The following certifications have been awarded:
- Good Clinical Practice (GCP)
- Diversity & Inclusion Research Conference (DIRC)
- OptymEdge
- IATA
Current research projects
- Macular and retinal diseases
- Systemic diseases and ocular effects
Spectrum
Description
- To describe the short and long term effectiveness of intravitreal aflibercept 8 mg in patients with naïve or pretreated nAMD or DME in routine clinical practice in each of the participating countries and overall
- To describe treatment pattern for the study eye in clinical practice in patients with naïve or pretreated nAMD or DME treated with intravitreal aflibercept 8 mg in routine clinical practice in each of the participating countries and overall
- To describe safety profile of intravitreal aflibercept 8 mg in patients with naïve or pretreated nAMD or DME in routine clinical practice in each of the participating countries and overall
Goal of the study
To describe the effectiveness of intravitreal aflibercept 8 mg in patients with naïve or pretreated nAMD or DME in routine clinical practice in each of the participating countries and overall.
Who can participate?
Recruitment completed
Study locations
Bern, Wallisellen, Aarau, Wetzikon
BASEC Number
2023-02079
Sponsor
Bayer
CAMBRIA-2
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Description
- The study duration will be approximately 14 years.
- The treatment duration for either arm in the study will be 7 years (84 months).
- The visit frequency for study assessments during the study treatment phase will be every 3 months until Month 7 (ie, Screening, Month 1, Month 4) and every 6 months up to 84 months. Additional visits can occur per investigator’s discretion and local SoC.
- The visit frequency during the follow-up phase will be every 12 months.
Goal of the study
The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant ± abemaciclib as compared to standard ET ± abemaciclib of patients with ER+/HER2- early breast cancer.
Who can participate?
The target population of interest in this study consists of patients with ER+/HER2- early breast cancer, with an intermediate-high or high risk of disease recurrence who have completed definitive locoregional therapy and have no evidence of disease.
Patients are recruited exclusively by the Tumor und BrustZentrum St. Gallen. We do not directly enroll patients, but rather provide ophthalmologic examinations for the study.
Study locations
Tumor und Brustzentrum St. Gallen and the ophthalmological examination in St. Gallen
BASEC Number
2023-504031-41-00
Sponsor
AstraZeneca
Contact details for referrers
Contact
Would you like to nominate a patient for a clinical study at Gutblick Research or learn more about a possible collaboration? Please contact us.
